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Spectrum of antibacterial activity
and mode of action of a novel trisstilbene bacteriostatic compound
Nikki Y. T. Man
Thomas V. Riley
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, Daniel R. Knight 2, Scott G. Stewart1, Allan J. McKinley1,
& Katherine A. Hammer 2

2,3,4

The spectrum of activity and mode of action of a novel antibacterial agent, 135C, was investigated using
a range of microbiological and genomic approaches. Compound 135C was active against Gram-positive
bacteria with MICs for Staphylococcus aureus ranging from 0.12–0.5 μg/ml. It was largely inactive
against Gram-negative bacteria. The compound showed bacteriostatic activity in time-kill studies and
did not elicit bacterial cell leakage or cell lysis. Checkerboard assays showed no synergy or antagonism
when 135C was combined with a range of other antibacterials. Multi-step serial passage of four S.
aureus isolates with increasing concentrations of 135C showed that resistance developed rapidly and
was stable after drug-free passages. Minor differences in the fitness of 135C-resistant strains and parent
wildtypes were evident by growth curves, but 135C-resistant strains did not show cross-resistance
to other antibacterial agents. Genomic comparison of resistant and wildtype parent strains showed
changes in genes encoding cell wall teichoic acids. 135C shows promising activity against Gram-positive
bacteria but is currently limited by the rapid resistance development. Further studies are required
to investigate the effects on cell wall teichoic acids and to determine whether the issue of resistance
development can be overcome.
Antimicrobial resistance (AMR) is one of the most problematic public health issues that society faces today. As
an example, the prevalence of methicillin-resistant Staphylococcus aureus (MRSA) increased from 5% in 1980 to
50% of documented S. aureus infections in 20001. The increase in AMR is placing significant pressure on essential
health care systems around the world2 as infections caused by resistant bacteria are associated with higher levels
of morbidity and mortality and increased health care costs3. Furthermore, in 2016 more than 2800 people died
from infectious diseases in Australia4, highlighting the need for effective antibiotic therapy as a critical component of reducing both morbidity and mortality associated with infectious diseases.
Naturally-occurring stilbenes are known for their diverse bioactivities5 including anti-cancer (phoyunbenes6,
halophilol A7 and combretastatins8), anti-diabetic (rumexoid9) and antimalarial activity (stilbenes isolated from
Artocarpus integer10). Many stilbene derivatives have also shown activity against bacteria11 including a compound
isolated from Combretum woodii leaves12.
A previous study of a promising antibacterial stilbene compound found in silico led to triacid derivative 135C
(Fig. 1). In this previous medicinal chemistry study, 135C was found to exhibit antibacterial activity13 against
several Gram-positive bacteria in vitro, including methicillin-resistant Staphylococcus aureus (MRSA), at concentrations comparable to those required for existing antibiotics14. Our reference compound 135C contains a
tri-carboxylic acid functionality and a tri-styrene motif, and its structural class is not seen in the current antimicrobial literature. Other natural stilbenes with antibacterial activity, such as resveratrol15, have been studied in
detail but none contain this tri-styrene motif. Thus, given that this compound falls outside any known existing
antibacterial classes, the benefits from developing it as a potential antibacterial agent are considerable, as there
may be a reduced likelihood of observing antibacterial cross-resistance16 and it is possible that the compound has
a novel mode of antibacterial action.
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Figure 1. Structure of compound 135C.
The aim of the current research was to continue investigations into the antibacterial activity of compound
135C. In particular, the spectrum of activity against a wide range of organisms was determined and the mode of
action was investigated. The spectrum of antibacterial activity and synergy with conventional antibacterial agents
was determined using broth microdilution techniques. Detection of the leakage of intracellular material that
absorbs at 260 nm, lysis of cells and time-kill experiments were also performed to investigate potential modes of
action. Lastly, the development of multi-step resistance to 135C was investigated by serial passage using four S.
aureus strains. A genomic comparison of the resultant 135C-resistant mutant strains and wildtype parent strains
was also performed.

Materials and Methods

Bacterial strains. Reference and clinical strains (n = 93) were obtained from the School of Biomedical
Sciences at The University of Western Australia (UWA) and PathWest Laboratory Medicine WA. The Gram
positive isolates (n = 71) comprised staphylococci (n = 40), streptococci (n = 20), micrococci (n = 10) and
Clostridium difficile (n = 1). The Gram negative isolates (n = 22) included Moraxella spp. (n = 10), Escherichia coli
(n = 3), Pseudomonas aeruginosa (n = 3), Prevotella bivia (n = 1) and Bacteroides spp. (n = 5).
Compounds.

Compound 135C was synthesised as described previously14 and purity was confirmed by 1H
and C NMR spectroscopy. Compound 135C was a yellow solid, and was stored under argon and protected from
light at −20 °C. Stock solutions of 135C in dimethyl sulfoxide (DMSO) were prepared fresh on each testing occasion and were diluted as required. The maximum concentration of DMSO present in bioactivity assays was 10%.
13

Susceptibility tests.

Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) were determined using the broth microdilution methods recommended by the Clinical and
Laboratory Standards Institute17. Briefly, compound 135C was serially diluted two-fold in 100 µL volumes of
sterile distilled water in a 96-well microtitre tray (Falcon, Becton Dickinson, USA). Inocula were prepared by
culturing organisms overnight on blood agar, then suspending several colonies in 0.85% saline. Each suspension
was then adjusted using 0.85% saline to a 0.5 McFarland turbidity standard. Suspensions were then diluted in
Mueller-Hinton broth to give a cell concentration of approximately 106 CFU/ml. Each well of the microtitre tray
was inoculated with a 100 µL volume of inocula and microtitre trays were incubated at 37 °C for 24 h, or 48 h for
anaerobes, under the appropriate conditions. For a subset of Gram-negative bacteria, MICs were also determined
in the presence of polymyxin B nonapeptide (PMBN) at a final concentration of 5 μg/ml. PMBN is a well-known
outer membrane permeabiliser18 and increased susceptibility in the presence of PMBN suggests that the Gram
negative outer membrane has a role in preventing the entry of antimicrobial compounds in the cell19. MICs were
determined as described above with the following adjustment: 135C was serially diluted two-fold in 50 μL volumes in a 96-well microtitre tray (Falcon, Becton Dickinson, USA), after which 50 μL of PMBN at 20 μg/ml was
added to each microtitre well. Novobiocin (0.5–512 μg/ml) was used as a positive control for assays with PMBN20.
For all susceptibility tests, MICs were determined visually as the lowest concentration of antibacterial agent preventing visible growth. For some assays, MBCs were determined by subculturing 10 µL volumes from non-turbid
wells, spot-inoculating onto blood agar and incubating for 24–48 h. The MBC was determined as the lowest concentration of antibacterial with no resultant growth in the subculture. MBCs were not determined for anaerobic
bacteria nor the assay with PMBN. Each organism was tested in triplicate and modal values were selected. DMSO
was tested in parallel as a solvent control.

Determination of antibacterial synergy. MICs of 135C in combination with a range of antibiotics
with varying mechanisms of action were determined against S. aureus NCTC 6571 to investigate whether synergy or antagonism occurred. The antibiotics tested were ciprofloxacin, rifampicin, vancomycin, erythromycin,
gentamicin and oxacillin. The checkerboard broth microdilution method was used as described previously21.
Briefly, each antibiotic was serially diluted two-fold in 50 μL volumes in a 96-well microtitre tray (Falcon, Becton
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Dickinson, USA), after which 50 μL of 135C at varying concentrations (ranging from 0.06–4 μg/ml) was added to
each dilution series. The remainder of the assay was performed as described above. For each well of the microtitre
plate that corresponded to an MIC, the fractional inhibitory concentration index (∑FIC) was determined using
the equation: ∑FIC = FICA + FICB = (MIC of drug A in combination/MIC of drug A alone) + (MIC of drug B
in combination/MIC of drug B alone). The ∑FICmin and ∑FICmax were determined as the lowest and the highest ∑FIC, respectively. The interaction was deemed synergistic if the ∑FIC was ≤ 0.5, additive if the ∑FIC was
between 0.5 and 1.0, indifferent if the ∑FIC was between 1.0 and 2.0 and antagonistic if the ∑FIC was > 2.022,23.
This assay was performed in triplicate per antibacterial agent/135C combination.

Cellular leakage and lysis. Bacteriolysis and cell leakage assays were performed as previously described24.

Inocula were prepared from an overnight culture of S. aureus NCTC 6571 in Mueller-Hinton broth (MHB) by diluting
to 0.5 McFarland in fresh MHB. Bacterial suspensions were then left untreated (untreated control) or were treated with
2, 32 (1 × MBC) and 320 μg/ml (10 × MBC) 135C. Treatments and the control were incubated at 35 °C with shaking at
80 rpm. Samples were removed immediately after inoculation (time 0), and further samples were taken at 15, 30, 60, 120
and 240 min. Cell lysis was determined by measuring the optical density (OD) of each sample at 600 nm. The leakage
of intracellular contents was determined by filtering samples (0.45 μm) to obtain cell-free filtrates and determining the
OD260 at time zero and 240 min only. The OD of all samples was determined against the appropriate blank at the appropriate wavelength. Each assay was performed in triplicate and mean values were determined.

Time-kill kinetics. Bacterial killing assays were performed as previously described24. Inocula were prepared as
described for the cell leakage and lysis assays and were exposed to 135C at 0 (untreated control), 32 and 320 μg/ml of
135C in MHB. Treatments and controls were incubated at 35 °C with shaking at 80 rpm and samples were removed
at 0, 15, 30, 60, 120 and 240 min. Samples were immediately serially diluted ten-fold in 0.01 M phosphate buffered
saline (PBS) at pH 7.0 and 10 μL aliquots were spot-inoculated in duplicate onto MHA. Agar plates were incubated
at 37 °C overnight before determining the viable count. The assay was conducted on two separate occasions.
Serial passage with compound 135C to evaluate resistance development. Four S. aureus strains
(NCTC 10442, ATCC 29213 and clinical isolates RPH 15913 and 3784546E) were investigated for the development of multi-step resistance to 135C by serially passaging in increasing concentrations of the compound, using
methods as previously described25. Briefly, MICs were determined using the CLSI broth microdilution method
as described above17. The optical density of all wells was then determined (at 600 nm) and serial passage was performed by removing the contents of the well with the highest concentration of 135C that had an OD600 value of
approximately 0.1, and adding this culture to a freshly prepared dilution series in a 96-well microtitre tray. This
was repeated at 24 h intervals for a total of 10 passages, for each of the four organisms. The compound concentration range of each new passage was based on the MIC from the previous passage. At the end of the serial passage
experiment, each organism was cultured from the highest turbid well onto blood agar (BA) and all were then passaged daily on drug-free media (BA) for 10 days. MICs of 135C were determined again after the third and tenth
drug-free passages. After three drug-free passages, MICs were also determined for ciprofloxacin, erythromycin,
gentamicin, oxacillin, rifampin, vancomycin, kanamycin and chloramphenicol to evaluate whether antibacterial
cross-resistance was evident. The entire experiment was performed four times.
Relative fitness of S. aureus isolates serially passaged with 135C. The relative fitness of strains was
evaluated as described previously26. Briefly, serially-passaged S. aureus isolates and parent strains were cultured overnight on brain heart infusion agar (BHIA) plates, then 2–3 well-isolated colonies were inoculated into 15 ml of brain
heart infusion broth (BHIB) and incubated at 37 °C with shaking at 80 rpm. After overnight growth, all cultures
were diluted to an OD600 of 0.01 and 150 μl of this was added to 15 ml of BHIB to give an inoculum concentration of
approximately 106 CFU/ml. Cultures were incubated at 37 °C with shaking at 125 rpm for 24 h. The OD600 of cultures
was determined every hour for 1–7 h and then at 24 h. The entire assay was performed four times.
Genomic DNA preparation and whole genome sequencing. Following subculture of S. aureus
isolates on blood agar for 24 h, genomic DNA was extracted using a Gentra Puregene Yeast/Bact. Kit [Qiagen,
Hilden, Germany] and multiplexed paired-end (PE) libraries were generated using standard Nextera XT protocols [Illumina, CA, USA]. Whole genome sequencing (WGS) of eight S. aureus strains (4 generated mutants, 4
wildtype) was performed using a MiSeq benchtop sequencer [Illumina], generating 300 bp PE reads. Sequence
data for this study has been deposited in the European Nucleotide Archive (ENA) under study PRJEB21492
(sample accessions ERS1797685-ERS1797692). To examine genetic differences between wildtype parent strains
and mutant progenitors, high-resolution single nucleotide variant (SNV) analysis was performed, as previously
described27. The highly annotated genome of S. aureus strain MRSA-252 [Genbank accession BX571856, multilocus sequence type (ST) 36] was used as a reference chromosome for read mapping (to a median depth of 45X
across the 2.9 Mbp chromosome, range 26.9–52.6X) and SNV calling28.

Results

Susceptibility tests.

Susceptibility testing of a range of aerobic bacterial species showed that compound
135C was active against Gram-positive bacteria and also active against the Gram negative species Moraxella
catarrhalis (Table 1). The most susceptible organism was S. aureus, with MICs of 135C ranging from 0.12–0.5 μg/
ml. However, the MBCs for all species tested were ≥ 32 μg/ml (Table 1). Given this large difference between the
MICs and MBCs, the activity of 135C was deemed to be bacteriostatic. When MICs against S. aureus NCTC 6571
were determined under anaerobic conditions, the MIC decreased from 0.5 to 0.004 μg/ml (seven doubling-dilutions). Susceptibility tests against a range of anaerobic bacteria showed an MIC of 16 µg/ml for Clostridium
difficile, and a range of 32–256 µg/ml for Prevotella bivia and five Bacteroides spp. strains.
Scientific REPOrTS | (2018) 8:6912 | DOI:10.1038/s41598-018-25080-w
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MIC (µg/ml)
Organism

n

Range

MIC50

MIC90

MBC (µg/ml)

Micrococcus spp.

10

8–>32

16

>32

>32

Moraxella catarrhalis

10

1–>32

8

32

>32

S. aureus (methicillin resistant)

10

0.12–0.5

0.25

0.5

32–256

S. aureus (methicillin susceptible)

10

0.25–0.5

0.25

0.5

32–128

Staphylococcus epidermidis

10

1–32

2

4

>32

Staphylococcus spp. (CNS)1

10

0.5–>32

4

>32

>32

Streptococcus pneumoniae

10

1–16

4

16

>32

Streptococcus pyogenes

10

8–32

8

16

>32

Table 1. Minimum inhibitory and bactericidal concentrations of 135C. 1CNS, coagulase-negative = Staphylococcus
hominis, S. warneri, S. saprophyticus, S. capitis and S. haemolyticus.

MIC (µg/ml)
Organism

135C alone

135C+PMBN

Novobiocin alone

Novobiocin+PMBN

E. coli ATCC 43889

>512

128

64

2

E. coli NCTC 10538

>512

32

256

4

E. coli ATCC 25922

>512

128

128

2

P. aeruginosa NCTC 6749

512

256

>512

n.d.

P. aeruginosa ATCC 27853

512

n.d.

256

1

P. aeruginosa ATCC 25668

512

512

512

8

Table 2. Minimum inhibitory concentrations of 135C for Gram-negative bacteria in the presence and absence
of PMBN. n.d. = no data. PMBN concentration 5 μg ml−1.

MICs in the presence of PMBN. The activity of 135C against E. coli and P. aeruginosa was enhanced in the

presence of PMBN (Table 2). The effect was more pronounced for E. coli than for P. aeruginosa, with the prior
exhibiting at least a three-doubling-dilution increase in susceptibility to 135C in the presence of PMBN.

Synergy experiments. Antibacterial synergy data were generated using oxacillin, gentamicin, erythromy-

cin, vancomycin, rifampicin and ciprofloxacin (Fig. 2). The ∑FIC was calculated to determine whether each combination of antibacterial agent/135C was considered synergistic, additive, indifferent or antagonistic (Table 3).
Although there were several ∑FICmin values that were less than 0.5, the results overall showed largely additive and
indifferent activity for all six antibacterial agents, indicating negligible synergistic activity with 135C.

Leakage, lysis and time-kill experiments. Treatment of S. aureus NCTC 6571 with the highest concentration compound 135C (320 μg/ml, 10 × MBC) did not lead to any decrease in OD600, indicating that cell lysis did not
occur. Similarly, experiments investigating whether exposure to 135C resulted in the leakage of intracellular contents
did not show an appreciable change in OD260 after 2 h, indicating that the leakage of intracellular materials (nucleic
acids) did not occur and that the cell membrane likely remained intact. Time-kill experiments with S. aureus NCTC
6571 did not show cell death at any concentration of 135C, with bacterial growth occurring in the presence of 2 µg/
ml and 32 µg/ml similar to the drug-free control. At 320 μg/ml (10 × MBC), cell viable counts remained similar to
time zero, indicating that growth was inhibited but that cell death did not occur under these conditions.
Multi-step serial passage of S. aureus isolates with compound 135C.

Four S. aureus isolates were
serially passaged with increasing concentrations of compound 135C to investigate the development of resistance.
After the first passage, MIC values for all four isolates had increased by at least 3-fold (Fig. 3) After ten passages
with increasing concentrations of compound 135C, MICs for all strains had increased from initial values of
0.12–0.25 μg/ml to 32–64 μg/ml. To investigate whether resistance was stable, isolates were subsequently passaged 10 times without 135C, and MICs were again determined. For all four strains, the MICs after 10 drug-free
passages were 32 μg/ml, which is similar to the final values (32–64 μg/ml) obtained after the 10 serial passages.
This indicates that changes in susceptibility were stable, and are possibly due to a defined genetic mutation. The
susceptibility of serially passaged S. aureus isolates was determined for a range of antibacterial agents selected to
cover five major mode of action targets for antibiotics within bacterial cells. Cross-resistance to an antibacterial
agent could indicate a shared, or at least similar, mode of antibacterial action16. However, parent and serially passaged resistant strains did not differ in susceptibility (Table 4). Therefore, this part of the study did not offer any
new information on the mode of action of compound 135C. Growth experiments conducted with both wildtype
and serially-passaged 135C-resistant strains (Fig. 4) showed minor differences in growth patterns, with the greatest difference seen for S. aureus ATCC 29213.

Genomic comparison of generated mutants and wildtypes. High-quality SNVs were detected in all
four S. aureus mutant strains, relative to their wildtype counterparts (Table 5). Three of the four 135C-resistant
Scientific REPOrTS | (2018) 8:6912 | DOI:10.1038/s41598-018-25080-w
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Figure 2. Isobolograms showing interactions between 135C and antibacterial agents. The dotted gradient line
represents the theoretical line of additivity.
Antibiotic

FICmin

FICmax

Interaction

Ciprofloxacin

0.5

1.125

Additive

Erythromycin

0.376

1.125

Additive

Gentamicin

0.375

1.125

Additive

Oxacillin

0.531

1.015

Additive

Rifampicin

0.375

1.125

Additive

Vancomycin

1

2.25

Indifferent

Table 3. Minimum and maximum Fractional Inhibitory Concentration (FIC) indices of antibacterial
agent/135C combinations.

strains showed nonsynonymous nucleotide changes (point mutations) in genes associated with teichoic acid biosynthesis (tagH, tagA, and tagG). These missense mutations resulted in codon changes and non-synonymous
amino acid changes in the respective tag proteins.
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Figure 3. Serial passage of S. aureus strains with 135C showing MICs over time. Data points are the geometric
mean of two independent experiments repeats, each conducted in duplicate (4 values per day per isolate).

Figure 4. Growth fitness of serially passaged S. aureus isolates. The W indicates the wild-type strain and P
indicates the passaged strain.

MIC (µg/ml)
Organism

Strain

CIP

ERY

GEN

OXA

RIF

VAN

KAN

CHL

135C

S. aureus NCTC
10442

Parent

1

1

2

>16

0.0078

1

8

8

0.25

S. aureus ATCC
29213
S. aureus 15913*
S. aureus
3784546E*

135C-passaged

0.5

1

1

>16

0.0078

1

4

8

>8

Parent

1

2

0.5

0.25

0.006

1

8

16

0.5

135C-passaged

0.5

1

1

0.5

0.0078

1

4

16

>8

Parent

>8

>16

>16

>16

0.0078

1

>128

16

0.25

135C-passaged

>8

>16

>16

>16

0.0039

2

>128

8

>8

Parent

>8

>16

2

>16

0.0078

1

8

16

0.5

135C-passaged

>8

>16

2

>16

0.0078

1

4

16

>8

Table 4. Evaluation of S. aureus isolates passaged with 135C for cross-resistance to antibacterial agents. CHL,
chloramphenicol; CIP, ciprofloxacin; ERY, erythromycin; GEN, gentamicin; KAN, kanamycin; OXA, oxacillin;
RIF, rifampin; VAN, vancomycin. *Clinical isolate.

Discussion

The current study showed that the novel compound 135C was active largely against Gram-positive bacteria and
confirmed the lack of activity observed previously against Gram-negative bacterial species14. Compound 135C
showed highest activity against S. aureus, and was slightly less active against other Gram positive organisms, for
Scientific REPOrTS | (2018) 8:6912 | DOI:10.1038/s41598-018-25080-w
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Strain

Position

WT

MUT

Locus tag

Gene

Variant Strand†

Protein change

Product description

551633

C

T

SAR0512

ftsH

—

—

Cell division protease FtsH

692985

T

C

SAR0647

tagH

A757G (minus)

p.Arg253Gly

Teichoic acid ABC transporter ATP-binding protein

S. aureus NCTC 10442 692787

G

T

SAR0646

tagA

G665T (plus)

p.Arg222Ile

Teichoic acid biosynthesis protein

S. aureus RPH 15913*

694216

C

G

SAR0648

tagG

C129G (plus)

p.Asn50Lys

Teichoic acid ABC transporter permease protein

838911

G

A

SAR0801

—

—

—

Putative glycosyl transferase

1721885

C

T

SAR1654

—

—

—

Conserved hypothetical protein (methyltransferase)

2506091

C

T

SAR2437

—

—

—

Putative transport protein

S. aureus 3784546E*

S. aureus ATCC 29213

Table 5. Analysis of heterozygous sites in wildtype and mutant strains of S. aureus. WT, wildtype. MUT,
mutant. MRSA-252 Genbank accession BX571856. *Clinical isolates. p. denotes amino acid change. †Base pair
change on forward (plus) or reverse (minus) DNA strand.
reasons that remain to be determined. Poor activity against most Gram-negative bacteria may be due to a number
of mechanisms including outer membrane impermeability and active efflux systems20. It has been shown previously that the outer membrane permeabiliser PMBN interacts with the lipopolysaccharide of the outer membrane
of Gram-negative bacteria, and PMBN has been used to sensitise different bacteria to many hydrophobic antibacterial agents such as novobiocin, erythromycin and clindamycin29. PMBN alone has negligible activity and does
not cause the leakage of periplasmic proteins from bacteria30 but allows the entry of hydrophobic antibacterial
compounds into the cell by facilitating hydrophobic diffusion through the outer membrane. The activity of 135C
was enhanced in the presence of PMBN, suggesting that the outer membrane has a role in limiting or preventing
the entry of this compound into the cell. Further evidence of outer membrane involvement is shown by the susceptibility of the unusual Gram negative M. catarrhalis to 135C, which is likely due to the lack of long O-antigen
polysaccharide chains in the lipopolysaccharide structure of its outer membrane31, which are normally present in
Gram-negative bacteria. The absence of these lipooligosaccharide chains results in the increased permeability of
the bacterial envelope31, which may contribute to the susceptibility of this organism to 135C.
When S. aureus species switch from aerobic to anaerobic growth, changes in gene expression occur, for example the presence of glycolytic enzymes, and comparatively low amounts of tricarboxylic acid cycle enzymes32. The
MIC of 135C against S. aureus NCTC 6571 decreased from 0.5 μg/ml to 0.004 μg/ml under anaerobic conditions.
This suggests that under such conditions, the compound may be oxidised to a less active derivative, or that the
compound may be metabolised differently under anaerobic conditions.
The mode of action of 135C against S. aureus was investigated using several different approaches. The first
approach was to investigate effects against the cell wall and cell membrane, as these are two major targets for
current antibacterial agents33 and experiments to quantify one or both are often performed to elucidate the mode
of action of novel antibacterial agent24. Unfortunately, the results from the cell leakage and lysis assays indicated
that neither of these sites are likely to be major targets for 135C.
Subsequently, studies investigating antibacterial synergy were conducted. Synergy between different antibacterial compounds can be determined using the checkerboard method where multiple concentrations of two different compounds are tested in combination. There are many examples of antibacterial combinations that have
been shown to be synergistic, and synergistic interactions have the potential to shed light on the mode of action of
an antibacterial agent. Examples include compounds that are active against the cell wall enhancing the uptake of
aminoglycosides, as well as combinations of agents active on the cell wall34. Compound 135C was tested in combination with antibacterial agents from different classes with known modes of action to broadly identify which
class 135C may fall into. Antibacterial synergy data was determined using oxacillin, gentamicin, erythromycin,
vancomycin, rifampicin and ciprofloxacin. The results showed only additive effects for all six antibacterial agents
and did not show any observable significant synergy nor antagonism (Fig. 2).
Investigation of the development of resistance to 135C by S. aureus isolates showed rapid and stable resistance,
which limits the potential usefulness of the compound. Often, the acquisition of bacterial resistance is accompanied by a fitness cost to bacteria35–37, typically evident as a reduction in growth rates in vivo38 and in vitro39,
decreased invasiveness40 or a lower cell density41. Data from the current study indicated only minor differences in
the fitness of parent and serially passaged strains, suggesting that fitness was not substantially altered.
Genomic comparison of the four 135C-resistant mutants to their wildtype parent strains provided interesting insight into a potential relationship between 135C and wall teichoic acids (WTAs) (Table 5). Of the four
135C-resistant strains, three contain mutations within the teichoic acid glycerol (tag) genes, tagH, tagA, and
tagG. These three genes are involved in protein products associated with teichoic acid biosynthesis (tagA), and
their ATP-binding cassette (ABC) transporter subunits (tagH and tagG)42–44. The changes identified in the
135C-resistant mutants suggest that WTAs may be the target site of 135C, or that the compound may disruption
of the regular function of WTAs. This finding is also helps to explain the lack of activity against Gram negative
bacteria, as teichoic acids are absent in Gram negative bacteria.
Of note was that the changes in all three tag genes were nonsynonymous substitutions. These missense mutations (single nucleotide alterations) result in codon changes that lead to different amino acids45. These changes
occurred in only three of the four strains, with these three strains all being methicillin-resistant whilst the fourth
strain is methicillin susceptible. The amino acid changes in S. aureus 3784546E and NCTC 10442 both involved
an arginine substitution. In both cases, the substitution led to amino acids with shorter (less flexible), more hydrophobic and non-polar side chains (glycine and isoleucine)46. For S. aureus RPH 15913, the mutation resulted
in an amino acid change from asparagine to lysine. The lysine side chain contains a longer (more flexible) and
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less hydrophobic moiety than asparagine, which is in contrast to what was observed in the previous two strains.
However, for all three strains the mutation resulted in a less polar amino acid47. The polarity of the amino acid
changes may be a significant factor if WTAs are the binding sites of 135C. Structurally, 135C is a symmetrical
molecule with three polar carboxylic acid moieties14. It is therefore plausible that a change in the polarity of an
amino acid in WTAs may have an effect on the ability of the acid moieties within this compound to hydrogen
bond to a potential binding site48,49. Therefore, from a structural perspective, the changes in the amino acid side
chains may be significant if the tag genes are indeed the binding sites of 135C.
It was interesting to note that S. aureus ATCC 29213 (methicillin-susceptible) was the only strain without a
change in a tag gene. A plausible explanation may be that this strains’ WTA genetic profile is different to that of
the methicillin-resistant strains. The mode of action of the β-lactam antibiotic methicillin involves the inhibition
of penicillin-binding proteins (PBPs), which are essential in the synthesis of the peptidoglycan layer that makes
up the cell wall50. Since WTAs are embedded in the peptidoglycan layer, the resistance mechanism of MRSA may
have also affected these sites44,51. It is also important to note that WTAs are classified as virulence factors42,52,
and as such, 135C may have a downstream effect on the ability of Gram-positive bacteria to proliferate in host
organisms.
To summarise, our study revealed 135C to be a bacteriostatic agent with activity against a range of
Gram-positive pathogens. The compound was largely inactive against Gram-negative bacteria, which may be due,
in part, to the impermeability of the Gram-negative outer membrane and absence of teichoic acids within the cell
wall. When combined with conventional antibiotics 135C did not show significant synergistic nor antagonistic
activity. The absence of leakage of bacterial cell contents and absence of cell lysis indicate that 135C is unlikely
to have a target within these sites. Resistance studies showed that S. aureus rapidly developed stable resistance to
135C, after as little as a single passage. Comparison of the whole genome sequence of the 135C-resistant mutants
to their wildtype counterparts revealed a change in teichoic acid-associated tag genes. Changes in these genes
indicate a possible interaction between 135C and WTAs as part of its mode of action. Additional studies with
bacterial strains that have specific WTA mutations53–55 may help to clarify the role of WTA in susceptibility to
135C. This may also offer insight into why S. aureus in particular, is highly susceptible compared to other Gram
positive organisms. In conclusion, lack of activity against Gram negative pathogens, absence of bactericidal activity and the rapid development of resistance all significantly limit the potential usefulness of the compound. It
remains possible that additional chemical modification of the compound may lead to further novel compounds
with improved efficacy, broader spectrum of activity and reduced resistance capacity.
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